1. Introduction {#s0005}
===============

Lymphatic filariasis (LF) and onchocerciasis (river blindness) are debilitating diseases caused by filarial nematodes, officially recognised as neglected tropical diseases (NTDs) ([@b0220]). Although these nematode infections are currently being effectively managed using mass drug administration (MDA) of drugs donated by large pharmaceutical companies ([@b0030; @b0040]), elimination is hampered by several challenges including the incomplete efficacy of available drugs against the long-lived adult filarial worms ([@b0105; @b0140; @b0020; @b0110]), problems associated with adverse events in areas of co-endemicity of *Loa loa* with either *Wuchereria bancrofti* or *Onchocerca volvulus* ([@b0055; @b0020; @b0165]), and the risk that filarial worms will develop resistance to the drugs currently available for MDA (reviewed in [@b0150; @b0130]).

Targeting the bacterial endosymbiont, *Wolbachia*, of these filarial nematodes offers solutions to these problems as the removal of *Wolbachia*, using tetracycline-based antibiotics, results in the slow death of the adult worm (reviewed in ([@b0165]) and, given that *L. loa* does not harbour these endosymbionts ([@b0120]), does not lead to adverse events following treatment ([@b0215; @b0200]). The use of doxycycline in field trials has demonstrated that this antibiotic can be used successfully to permanently sterilise adult female worms and, if given for an appropriate length of time, lead to a macrofilaricidal effect (reviewed in [@b0085; @b0070; @b0165]); an important improvement over current treatments. The current 4--6 weeks of daily treatment, is the main barrier to wide-spread scale-up of this treatment regimen into MDA programmes due to logistical constraints, although community-directed treatment with doxycycline for six weeks, achieving a therapeutic coverage of 73.8% and 98% compliance, is feasible and effective in restricted populations ([@b0215; @b0160]). Doxycycline, however, also has limitations for mass use due to contraindications that make it unsuitable for treating children under eight and pregnant women (reviewed in [@b0085; @b0070]).

The A·WOL Consortium was established to find a new anti-wolbachial drug or combination of drugs that is compatible with MDA with a secondary goal to optimise regimens using the currently known active antibiotics (doxycycline and rifampicin) ([www.a-wol.com](http://www.a-wol.com){#ir0010}; [@b0095; @b0170]). Screening large chemical libraries to identify compounds with macrofilaricidal activity has been hindered in the past by the lack of efficient screening assays with available assays being labour intensive ([@b0180; @b0135; @b0185; @b0190]). To overcome this limitation the A·WOL Consortium developed a *Wolbachia* cell-based assay with a quantitative PCR (qPCR) readout which has been optimised as an *in vitro* drug screening tool. Here, we briefly describe the validation of this assay which utilises a *Wolbachia pipientis*-containing *Aedes albopictus* cell line (C6/36 (*w*AlbB)), in a 96-well format, and quantifies the *16S* rRNA gene copy number of intracellular *Wolbachia* bacteria in the presence or absence of a drug, as well as an ATP--luminescence based cytotoxicity assay to examine off-target toxic effects of the drug on the mosquito host cells. The assay can be adapted to automated high throughput-screening and represents a rapid, sensitive and efficient assay for screening chemical libraries to identify anti-*Wolbachia* compounds. Hits from this primary *in vitro* cell-based screening assay are then selected for progression down the screening pipeline into both *in vitro* and *in vivo* nematode screening.

Repurposing or repositioning of drugs provides a less risky route to drug discovery given that candidates will already have well-known safety and pharmacokinetic profiles ([@b0010; @b0175; @b0125; @b0060]). Here, we describe screening efforts against *Wolbachia* using the A·WOL assay to screen a compound library of 2664 approved drugs, bioactive compounds and natural products (CRX; CombinatoRx Singapore). This strategy identified 121 hits that had anti-*Wolbachia* activity, of which 69 were orally available hits from different drug categories, and several drugs were progressed further down the screening pipeline into *in vitro* nematode screening assays and the primary *in vivo* screening model (*Litomosoides sigmodontis* mouse model). This approach has identified several classes of registered drugs with anti-*Wolbachia* activity, which has expanded the options for improving macrofilaricidal therapeutic regimes against onchcocerciasis and lymphatic filariasis.

2. Materials and methods {#s0010}
========================

2.1. *In vitro Wolbachia* cell-based screening assay {#s0015}
----------------------------------------------------

An *A. albopictus* cell line C6/36 (ATCC number CRL-1660) stably infected with *W. pipientis w*AlbB (C6/36 (*w*AlbB)) was routinely cultured in L15 Leibovitz medium containing 2 mM [l]{.smallcaps}-glutamine, 1% non-essential amino acids, 2% tryptose phosphate broth (Sigma-Aldrich, UK), and 5% heat-inactivated FCS (Cambrex Bio Science, Walkersville, MD) at 26 °C ([@b0195]). A C6/36 (*w*AlbB) cell-based assay developed to screen drugs/compounds active against *Wolbachia in vitro* was used as previously described ([@b0090]). C6/36 (*w*AlbB) cells, sub-cultured 24 h previously, were seeded at 10,000 cells per well in 96-well flat bottom culture plates. Test compounds were dissolved in DMSO (Sigma) and diluted to appropriate concentration (μM) in culture medium, added to test wells and cells cultured in a total volume of 200 μl at 26 °C for 9 days. Medium alone and vehicle-treated (DMSO) medium were used as negative controls. Compounds and controls were added in triplicate and medium/drug was replaced on day 4. At the end of the screening assay, samples were collected by washing adherent cells once in sterile Dulbecco's PBS (Sigma) and adding 150 μl Wizard® SV Lysis Buffer (Promega, UK) for genomic DNA (gDNA) extraction.

In total, 2664 compounds from the CRX library, plated onto 37 master plates (72 compounds per plate), were screened at 10 μM in comparison to the gold standard doxycycline (7 μM) (Sigma). Cytotoxicity was measured in parallel using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega), according to the manufacturer's instructions. The level of cytotoxicity for each compound was determined by comparing the CellTiterGlo® luminescence readout against the vehicle-treated control wells, with compounds that reduced the % luminescence by 30% or greater being classed as cytotoxic. Screening was executed with a "front loading" of the library wherein approximately 200 anti-infectives were used in the first three master plates to maximise the number of hits in the first phase of screening. A pre-production run was done to evaluate assay performance and dynamic range with Z′ factor being used as a primary quality control tool for data generation/analysis. With acceptable Z′ factors achieved (greater than 80% of the plates showed Z′ factors of 0.4 and above), the assay was validated for use.

Hits were cherry-picked from master plates and examined in a titration series (6 doses from 10 to 0.3 μM) for dose response effects set up in quadruplicates (inter and intra plate duplicates) and were also tested in parallel for cytotoxicity. Hits were also validated using compounds sourced externally, where available. Prioritisation of hit compounds for further screening was based on the following criteria: (1) suitability/approval status, (2) potency in screening assay, (3) repeat validation (both library and sourced compounds), (4) paediatric use, and (5) pregnancy category (US--FDA categories, [www.fda.gov](http://www.fda.gov){#ir0015}).

2.2. *In vitro Onchocerca gutturosa* screening assay {#s0020}
----------------------------------------------------

Adult male *O. gutturosa* were dissected from the nuchal ligament connective tissues obtained from naturally infected cattle in The Gambia, as previously described ([@b0185]). Worms were maintained individually in the wells of a 24-well plate in 2 ml of Minimum Essential Medium containing 10% heat-inactivated FCS, 200 U/ml penicillin, 200 μg/ml streptomycin and 50 μg/ml amphotericin B (Sigma), at 36.5 °C with 5% CO~2~ for 24 h until the addition of drugs. Compounds, dissolved in 99% DMSO, were prepared as previously described ([@b0185]) in medium and each compound was tested against ten individual worms for 5 days. Daily microscopic observations were carried out to determine worm motility using a scale of 0 (immobile) to 10 (maximum motility) and the mean % motility reduction was derived by the comparison to untreated controls. At assay termination, each group of 10 worms (per compound) were transferred to RNAlater (Ambion, Applied Biosystems, UK) for 24 h at 4 °C and stored at −20 °C for gDNA extraction from individual worms at a later date.

2.3. *In vivo L. sigmodontis* screening assay {#s0025}
---------------------------------------------

Treatment groups of BALB/c female mice (6--8 week old) received intraperitoneal (IP) injections with the test compounds, in comparison to doxycycline, at appropriate concentrations (MKD, mg/kg/day) for 14 days beginning the day after natural mite (*Ornithonyssus bacoti*) infection with *L. sigmodontis*. Compounds were formulated in appropriate delivery vehicles (eg. methacycline was formulated in 0.5% hydroxypropyl methylcellulose, HPMC) and doses calculated based on the recommended human dosage and in a volume of 10 ml/kg based on body weight. At 35 days post-infection, worms were recovered from the pleural cavity, counted, staged for development and measured for length (mm). Worms were frozen at −80 °C for gDNA extraction. All animal experiments were performed according to the European Union animal welfare guidelines. All protocols were approved by the Landesamt für Natur, Umwelt und Verbraucherschutz, Cologne, Germany (AZ.: 8.87-50.10.35.08.024).

2.4. DNA isolation and quantitative real-time PCR (qPCR) {#s0030}
--------------------------------------------------------

Genomic DNA was extracted from C6/36 (*w*AlbB) cell lysates using the Wizard® SV 96 Genomic DNA Purification System (Promega) according to the manufacturer's instructions and eluted in 100 μl water. Quantification of the ribosomal genes; *W. pipientis 16S* and *A. albopictus 18S*, was performed as described previously ([@b0115]) with modifications. Briefly, qPCR was carried out on a DNA Engine PTC-200 thermocycler (MJ Research, GRI, UK) with Chromo4 real-time PCR detection system (Bio-Rad Laboratories Ltd, UK) under the following conditions: 95 °C for 15 min, 40 cycles of 95 °C for 15 s, 55 °C for 30 s, and 72 °C for 15 s; and melting curve analysis between 50 and 95 °C to confirm the specificity of the amplification products. qPCR reactions were performed in 20 μl Quantitect SYBR Green (Qiagen, UK) reactions containing 1 μl gDNA for *18S* or 2 μl gDNA for *16S*, 0.2 μM of each primer ([Supplementary Table S1](#s0085){ref-type="sec"}) in 1× SYBR Green PCR reaction mix. Quantification was calculated by reference to a linear standard curve of log 10 diluted (5 × 10^6^--5 × 10^0^) full-length amplicons synthesised as single-stranded oligonucleotides (Sigma--Genosys, UK).

Following *in vitro* culture, gDNA was extracted from individual adult male *O. gutturosa* using the Wizard® SV 96 Genomic DNA Purification plate (Promega) and QiaAmp DNA mini-kit reagents (Qiagen) and eluted in 100 μl water. Quantification of the *Wolbachia* surface protein (*wsp*) and nematode glutathione *S*-transferase (*Ov-gst*) gene copy numbers was performed by qPCR carried out on a DNA Engine PTC-200 thermocycler (MJ Research) with Chromo4 real-time PCR detection system (Bio-Rad) under the following conditions: 95 °C for 15 min, 40 cycles of 95 °C for 15 s, 57 °C (*gst*) or 60 °C (*wsp*) for 30 s, and 72 °C for 15 s; and melting curve analysis between 60 and 97 °C. qPCR reactions were performed in 20 μl Quantitect SYBR Green (Qiagen) reactions containing 1 μl gDNA, 3 mM MgCl~2~ and 0.3 μM of each primer ([Supplementary Table S1](#s0085){ref-type="sec"} for *gst* or 2 μl gDNA, 3.5 mM MgCl~2~ and 0.35 μM of each primer ([Supplementary Table S1](#s0085){ref-type="sec"}) for *wsp*, in 1× SYBR Green PCR reaction mix. The gene copy number was determined using a gene specific standard curve of plasmid DNA.

At 35 days post-infection, *L. sigmodontis* worms were recovered from the pleural cavity and gDNA extracted using the QiaAmp DNA mini-kit (Qiagen) according to the manufacturer's instructions and eluted in 50 μl water. Quantification of the *Wolbachia ftsZ* (*wLs-ftsZ*) and *L. sigmodontis* β-actin (*Ls-act*) gene copy numbers was performed by qPCR ([@b0005; @b0155]) carried out on a RotorGene 3000 (Corbett Research, Sydney, Australia). The following cycling conditions were used: 95 °C for 15 min, 45 cycles of 95 °C for 15 s, 58 °C for 45 s, and 72 °C for 15 s; and melting curve analysis between 62 and 99 °C. qPCR reactions were performed in 10 μl reactions volumes using the following conditions: 1xPCR buffer (Qiagen), 0.2 mM dNTPs, 3 mM MgCl~2~, 0.1 μl SYBR Green (1:1000 dilution of stock in DMSO; Roche, Mannheim, Germany), 0.25 U HotStar Taq polymerase (Qiagen) and 2 μl DNA. The gene copy number (copy numbers/μl) was determined using a gene specific standard curve of plasmid DNA.

For all qPCR reactions results were expressed as *Wolbachia* gene:host gene ratios to normalise the data and obviate differences in the quality and quantity of DNA. The log drop in the ratio in comparison to the control gives a quantitative measure of the effect of the compound on *Wolbachia*.

2.5. Statistical analysis {#s0035}
-------------------------

Student *t*-test was performed for statistical analysis using Prism (GraphPad Software, LaJolla, CA).

3. Results {#s0040}
==========

3.1. Development of a screening assay which identifies anti-*Wolbachia* activity *in vitro* {#s0045}
-------------------------------------------------------------------------------------------

In this report, we describe the development, validation and use of an assay for the *in vitro* cell-based screening of anti-*Wolbachia* compounds. Using doxycycline as a gold-standard, critical features such as reproducibility, assay duration and dynamic range were evaluated. Initial experiments were conducted over 21 days in order to assess the dynamic range of the doxycycline response over time ([Fig. 1](#f0005){ref-type="fig"}). Assay quality and robustness were determined during the optimisation as well as during the screening process by calculation of the statistical parameters *Z* (and Z′) ([@b0225]), and having achieved acceptable Z′ factors the assay was validated for use ([Supplementary Tables S2 and S3](#s0085){ref-type="sec"}). Acceptable Z′ factors were achieved at day 9 but not at day 5 ([Supplementary Table S2](#s0085){ref-type="sec"}), demonstrating that the optimal duration of the assay was 9 days. A pre-production run of 8 replicate plates (master plate MS-250501) was used to calculate the intra-plate variability (Z′ factors) of the *16S* qPCR assay read-out ([Supplementary Table S3](#s0085){ref-type="sec"}). Greater than 80% of the plates showed Z′ factors of 0.4 and above and signal window of 2 allowing us to be confident that the assay could be used for screening of the CombinatoRx (CRX) library.

3.2. Screening of the human pharmacopeia identified drugs with activity against *Wolbachia* {#s0050}
-------------------------------------------------------------------------------------------

The CRX library of 2664 compounds, representing the approved human drug pharmacopoeia, was screened using the validated assay. Initial screening was executed with a "front loading" of the library where 200 anti-infectives were used in the first three master plates to maximise the number of hits in the first phase of screening and further validate the assay prior to screening the complete library. From the 2664 compounds tested, we identified 121 compounds that inhibited *Wolbachia* by 0.5 logs (70% inhibition at 10 μM); this represents a primary hit rate of 4.54%. We then further defined hits as those compounds that along with these *in vitro* hit criteria (⩾0.5 logs inhibition of *Wolbachia 16S* and ⩽30% cytotoxicity) are also available in an oral formulation in order to align our hit picking strategy to the Target Product Profile (TPP) criteria.

Of the 121 active compounds, 69 compounds (2.59% of the total screened), over several drug classes ([Table 1](#t0005){ref-type="table"}), satisfied hit criteria ([Table 2](#t0010){ref-type="table"}). Hits identified in the screening campaign were interesting and diverse ([Table 1](#t0005){ref-type="table"}), and included anti-infective compounds (35%) such as antibiotics, anti-viral, anti-parasitic and anti-fungal compounds, as well as non anti-infective compounds (65%) constituting anti-psychotic compounds, natural products/nutraceuticals, receptor antagonists, anti-hypertensives, muscle relaxants, non-steroidal anti-inflammatory drugs and other drug classes, pointing towards potentially novel mechanisms of countering intra-cellular *Wolbachia* bacteria which could be exploited.

Encouragingly, we identified hits among classes of antibiotics (the tetracyclines, rifamycins and fluoroquinolones) previously shown to reduce *Wolbachia* ([@b0080; @b0180; @b0065; @b0135; @b0050; @b0205; @b0185]), thus giving us confidence in the screening outcome. Out of the 69 hits, 24 compounds inhibited *Wolbachia* by 1 log or more which corresponds to 90% inhibition. Moreover, 10 of these 24 compounds showed comparable or better activity than that of doxycycline (⩾1.6 logs or 95% inhibition). Compounds which were equivalent to or better than doxycycline *in vitro* were: ciprofloxacin hydrochloride, ethosuximide, indomethacin, kitasamycin, methacycline hydrochloride, minocycline, paromomycin sulfate, piracetam, rifapentine, and sulfamethizole ([Table 2](#t0010){ref-type="table"}).

3.3. Validation and prioritisation of hits {#s0055}
------------------------------------------

To further characterise and validate the hit compounds, dose response assays were performed with 66 of the hit compounds to examine the dose-dependent effects. Of the re-tested compounds, 16 compounds failed to show any activity (\>50% inhibition of *Wolbachia*) in the repeat assays and were termed as drop-outs ("validated -- library compound" column, [Table 2](#t0010){ref-type="table"}). The remaining compounds showed varying degrees of activity from 98% to 50% inhibition at 10 μM. In the dose response assays, 36 of the hits showed a dose response in the dose range tested (e.g. paromomycin sulfate and loratadine), while other hits did not show a dose response. Ten compounds were active at all tested concentrations to the same extent (e.g. methacycline hydrochloride and sulfaguanidine), while four compounds showed activity only at the highest concentration (10 μM) (e.g. ciprofloxacin hydrochloride and curcumin). In addition, hit compounds were further validated by re-screening using, where available, externally sourced compounds (30/69 compounds) ("validated--sourced compound" column, [Table 2](#t0010){ref-type="table"}).

The hit compounds were then ranked based on the following criteria: (1) suitability/approval status, (2) potency in screening assay, (3) repeat validation (both library and sourced compounds), (4) paediatric use, and (5) pregnancy category (US--FDA categories, [www.fda.gov](http://www.fda.gov){#ir0020}), and then were prioritised for progression through the A·WOL screening pipeline into *in vitro* nematode screening assays and the primary *in vivo* screening model (*L. sigmodontis* mouse model) ([Table 2](#t0010){ref-type="table"}). Seventeen compounds, that were validated using both library and sourced compounds, were classed as top priority hits. A further 21 compounds, that were validated using library compound only, were classed as second priority hits and ranked using the defined criteria. The remaining 31 hits were classed as de-prioritised hits for various reasons. For example, ciprofloxacin was de-prioritised as it had previously been tested in the *in vivo* mouse model ([@b0080]), as well as compounds that were subsequently found to be inactive, or variably active, in repeat screening. Furthermore, compounds that had not been validated using either library compound or sourced compound as well as hits that were anti-neoplastics, clinical trial compounds or compounds currently only used in livestock were also de-prioritised.

3.4. The effect of a selection of hits on the motility and *Wolbachia* load of filarial worms *in vitro* {#s0060}
--------------------------------------------------------------------------------------------------------

Due to the promising results obtained in the *in vitro* cell-based assay screen some compounds were assessed more fully using *in vitro* nematode assays for proof-of-concept in our screening strategy. Further examination of active antibiotic classes that emerged as hits in the *in vitro* cell-based screening assay was conducted using an *O. gutturosa* adult nematode screen. A dose response assay using fourfold dilutions from 12.5 to 0.195 μM was used. All antibiotics tested showed only marginal or no effect on motility (data not shown) indicating that there was no direct toxicity against the nematode. The fluoroquinolones ciprofloxacin and moxifloxacin as well as the rifamycin rifapentine greatly reduced the *Wolbachia* load at all concentrations tested ([Table 3](#t0015){ref-type="table"}). While doxycycline also reduced the *Wolbachia* load, the response across the different concentrations was more variable than the other compounds. Overall, no dose responses were observed for any of the compounds tested, suggesting a ceiling effect of the concentrations used. Taken together, these *in vitro* worm experiments demonstrate good translation of hits from the *in vitro* insect cell based assay to nematode *Wolbachia* within their natural hosts.

3.5. The effect of prioritised hits on the length and *Wolbachia* load of *L. sigmodontis in vivo* {#s0065}
--------------------------------------------------------------------------------------------------

Due to their *in vitro* activity the prioritised hits were tested in the *L. sigmodontis-*mouse model ([@b0075; @b0080; @b0205]), using intra-peritoneal dosing. A total of 15 *in vitro* hit compounds were screened using doses calculated based on approved human doses and compared to doxycycline ([Table 4](#t0020){ref-type="table"}). This included ciprofloxacin, which, although had been deprioritised due to previous work, was retested given its activity in the *in vitro O. gutturosa* screen. Dose responses were also performed on a selection of these compounds ([Table 4](#t0020){ref-type="table"}).

Four compounds, methacycline, minocycline, rifapentine and sparfloxacin, significantly reduced the worm length and the *Wolbachia* load at the standard doses tested (*P* \< 0.05) ([Table 4](#t0020){ref-type="table"}). Methacycline treatment resulted in significant reductions in both worm length and *Wolbachia* load at both 50 and 10 MKD doses. Interestingly, when treated with methacycline at 50 MKD the reduction in *Wolbachia* load was significantly greater than from worms recovered from mice treated with the same dose of doxycycline (*P* \< 0.05). In contrast, loratadine had no effect on either worm length or *Wolbachia* load as measured by *Wolbachia ftsZ* copies at any dose tested. Ciprofloxacin also did not reduce worm length or *Wolbachia* load ([Table 4](#t0020){ref-type="table"}), confirming a previous report using this model ([@b0080]), while sparfloxacin did produce a significant reduction in both (*P* \< 0.01). Further experiments using other members of this class have shown that levofloxacin is inactive, while moxifloxacin is active (data not shown), demonstrating diversity within this class. As part of the drive to reduce the duration of treatment for anti-*Wolbachia* therapy, a reduction in doses and treatment durations have also been investigated using this model. While the reduced regimen tested for sparfloxacin did not significantly affect worm length or *Wolbachia* numbers, a reduced minocycline dose and treatment duration (25 MKD for 10 days) significantly reduced the *Wolbachia* load (*P* \< 0.0001) and this reduction was also significantly greater than *Wolbachia* reduction following the equivalent doxycycline treatment (*P* \< 0.05) ([Table 4](#t0020){ref-type="table"}).

4. Discussion {#s0070}
=============

Here we describe the development of an *in vitro Wolbachia* screening assay and the subsequent use of this assay to screen the complete human pharmacopoeia, with a view to drug repurposing for filariasis. Repurposing or repositioning of drugs provides a less risky route to drug discovery given that candidates will already have well-known safety and pharmacokinetic profiles ([@b0010; @b0175; @b0125; @b0060]).

This study identified 121 compounds with *in vitro* activity against *Wolbachia*, 69 of which satisfied our hit criteria. These hits included, as expected, numerous anti-infective compounds (35%). These included drugs from classes known to show some efficacy against *Wolbachia*, namely the tetracyclines, rifamycins and fluoroquinolones ([@b0080; @b0180; @b0065; @b0135; @b0050; @b0205; @b0185]). Interestingly, many were non anti-infective compounds (65%) encompassing several different drug classes, thereby pointing towards potentially novel mechanisms of action. Although mechanisms of action have not been investigated here, the number of non anti-infective compounds that demonstrated activity against *Wolbachia in vitro* offers several interesting avenues to pursue. As well as the possibility that these compounds are acting on the bacteria directly, a perturbation of the complex interplay between the *Wolbachia* and their host cells must also be considered. Indeed, interfering with the *Wolbachia*-host relationship through chemotherapy may be just as effective as targeting the bacteria themselves. The involvement of *Wolbachia* in the maintenance of host homeostasis has been referred to in previous studies, especially in relation to oxidative stress regulation ([@b0025; @b0100]). Antioxidants were among the compounds active against *Wolbachia* in this study and this class is currently being mined further to inform the potential repurposing and repositioning of these drugs. Autophagy, a conserved intracellular defence mechanism, has recently been demonstrated to be play a key role in controlling *Wolbachia* populations ([@b0210]) and therefore components of the pathways involved in this mechanism may be the targets of some of non anti-infective compounds that were hits. This aspect of the screening outcomes is also currently being investigated. Furthermore, the presence of these hits offers the potential for combining drugs, such as antibiotics and non-antibiotics for synergistic effect ([@b0045]).

As expected with any screening strategy, many of the compounds found to be hits *in vitro* failed at the *in vivo* model stage. Minocycline, methacycline, rifapentine and sparfloxacin demonstrated activity in the *L. sigmodontis* mouse screening assay. The drop-outs can be explained in a variety of ways. Firstly there may be differences in drug susceptibility between insect and nematode *Wolbachia*, but, more likely, they may also reflect issues of penetration across the nematode cuticle or bioavailability within the mouse model. As the compounds within the CRX library were registered drugs, the *in vitro* nematode screens described here were not a key decision-making checkpoint, as they were for the screening of other focused and diversity libraries containing novel chemical entities. The prioritised hits progressed directly into the primary *in vivo* screen, thus making it impossible to distinguish between issues of penetration or bioavailability. The lack of activity of loratadine on both *L. sigmodontis* length and *Wolbachia* load can potentially be explained by the dosage used. Generally, the recommended human dosages of anti-histamines are very low and, given that this dose of loratadine was used to calculate doses for this experiment, this could be a factor in its lack of activity. Alternatively, the relatively weaker activity of loratadine in the cell assay in comparison to the anti-bacterial hits may make it difficult to translate to the *in vivo* situation. Certainly, as the A·WOL screening process has been developed and improved, now utilising a high content imaging platform ([@b0035]), potency has become a more important driver of *in vivo* experiments.

Pharmacological factors may also explain the more surprising differences observed between closely-related drugs within the same class. The fluoroquinolone antibiotics sparfloxacin and ciprofloxacin were demonstrated to be active *in vitro*. Ciprofloxacin has previously been shown to have either no activity ([@b0065]) or modest activity ([@b0050]) in other cell-based *Wolbachia* assays, and the fact that this activity extended to the *in vitro* nematode screen in our screening strategy, suggests that the optimisation of our cell-based screening assay has increased the detection of active compounds. Despite this, of the two fluoroquinolone antibiotics tested, only sparfloxacin was active *in vivo*, thus demonstrating that pharmacological parameters must differ between members of the class in our screens. Further studies in the *L. sigmodontis* model conducted recently have extended this knowledge of diversity within the fluoroquinolone class by demonstrating that moxifloxacin is active, thereby confirming our result in the *O. gutturosa in vitro* model, yet levofloxacin is inactive (S. Specht, unpublished observations). The inconsistency in the activity of ciprofloxacin throughout previous work and the absence of studies using other fluoroquinolones has meant that this class has largely been overlooked as a potential source of novel anti-*Wolbachia* compounds. DNA gyrase can now be considered as a valid chemotherapeutic target of *Wolbachia*. The *L. sigmodontis* model demonstrated increased potency of minocycline over doxycycline *in vivo*, adding weight to a previous observation made using nematodes *in vitro* ([@b0185]). Minocycline is considered to be more lipid-soluble than doxycycline ([@b0015]) and this may therefore lead to higher concentrations of the drug reaching the appropriate tissues, such as the nematode hypodermal cords, in which the *Wolbachia* reside. Work is currently ongoing to determine whether any increased potency observed across the models with the fluoroquinolones and tetracyclines translates into reduced treatment duration: a potentially important improvement when considering implementation of an anti-*Wolbachia* treatment for mass drug administration programs. Further outcomes based on double and triple combinations are also progressing through the screening strategy.

The development of the 96-well *in vitro* cell-based assay described here has, in itself, been a major development in the study of the biology and chemotherapy of *Wolbachia. Wolbachia* are obligate intracellular bacteria and previous cell-based screening had used either flasks ([@b0065]) or 24-well plates ([@b0050]) therefore deeming large-scale screening studies unachievable within the five-year project. The robustness of this assay has already allowed, prior to the publication of this report, other studies to provide further insights into *Wolbachia* biology ([@b0090; @b0145; @b0210]). Furthermore, this screening assay has since been further optimised and up-scaled ([@b0035]) to the extent that the A·WOL consortium has now screened tens of thousands of compounds from both focused and diversity compound libraries for anti-*Wolbachia* activity, a selection of which are moving down the screening funnel. The funnel, too, has been further optimised to streamline the A·WOL screening strategy and thus maximise hit discovery ([@b0095]).

These experiments not only provided a proof of concept of our cell-based assay and screening platform but also identified potential lead candidates that are better than the gold standard doxycycline in reducing *Wolbachia* load *in vivo*. A·WOL is currently testing in clinical trials whether refined regimes of registered anti-*Wolbachia* drugs can translate into improved regimes for macrofilaricidal therapy of onchocerciasis and lymphatic filariasis.
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![Dynamics of cell and *Wolbachia* response to doxycycline over 21 days. *Wolbachia* growth was assessed by qPCR targeting the *16S* rRNA gene (A). C6/36 cell growth was assessed by qPCR targeting the *18S* rRNA gene of *Aedes albopictus* (B). Data was normalised using the ratio of *16S* copies to *18S* copies (C).](gr1){#f0005}

###### 

Distribution of drug classes across 69 hit anti-*Wolbachia* compounds. 121 compounds inhibited intracellular *Wolbachia* bacteria by 0.5 logs or more. Out of these, 69 belong to diverse classes of approved drugs and are available in an oral formulation and hence constitute hits for further analysis.

  Drug class                          Number of hits   Percent of hits (%)
  ----------------------------------- ---------------- ---------------------
  Anti-infectives                     24               35
  Anti-psychotics/anti-convulsants    8                12
  Natural products/nutraceuticals     7                10
  Receptor antagonists                6                9
  Anti-hypertensives                  6                9
  Muscle relaxants                    5                7
  Others                              5                7
  Non-steroidal anti-inflammatories   4                6
  Anti-neoplastic agents              4                6

###### 

Prioritisation of hit compounds. The 69 hits obtained in single agent screening were first validated using either library or sourced compound, where available, and then prioritised for further screening based on (1) suitability/approval status, (2) potency in 16S assay, (3) repeat validation (both library and sourced compounds) (4) paediatric use and (5) pregnancy category (US-FDA pregnancy categories). Compounds were classed as top priority, second priority or deprioritised hits and are listed in the following table in rank order based on activity in the cell-based screen. nd = not determined, ? = evidence unclear.

  Compound                        16S log drop   Teratogenic/embryocidal   Pregnancy category[a](#tblfn1){ref-type="table-fn"}   Use in pediatric indications               Validated-library compound   Validated-sourced compound          Characteristics                         Comments
  ------------------------------- -------------- ------------------------- ----------------------------------------------------- ------------------------------------------ ---------------------------- ----------------------------------- --------------------------------------- -------------------------------------------------------
  *Top priority hits*                                                                                                                                                                                                                                                                
  Methacycline hydrochloride      1.8            Yes                       D                                                     Not evaluated in children under 8 years    Yes                          Yes                                 Anti-biotic                             
  Indomethacin                    1.7            None observed             C                                                     Not evaluated in children under 14 years   Yes                          Yes                                 Non-steroidal anti-inflammatory         
  Paromomycin sulfate             1.7            Yes                       D                                                     Approved                                   Yes                          Yes                                 Anti-biotic                             
  Rifapentine                     1.7            Yes                       C                                                     Not evaluated in children under 12 years   Yes                          Yes                                 Anti-TB                                 
  Minocycline                     1.6            Yes                       D                                                     Not evaluated in children under 8 years    Yes                          Yes                                 Anti-biotic                             
  Naftopidil                      1.2            Not evaluated             ?                                                     Not evaluated                              Yes                          Yes                                 Anti-hypertensive                       Treatment of enlarged prostrate
  Abacavir Sulfate                1              Yes?                      C                                                     Yes                                        Yes                          Yes                                 Anti-viral                              
  Sparfloxacin                    1              Yes                       C                                                     Not evaluated in children under 18 years   Yes                          Yes                                 Anti-biotic                             
  Docusate Calcium                0.8            Yes                       C                                                     Not evaluated in children under 3 years    Yes                          Yes                                 Laxative                                
  Loratadine                      0.8            None observed             B                                                     Not evaluated in children under 2 years    Yes                          Yes                                 Allergy medication                      
  Ethoxzolamide                   0.7            ?                         ?                                                     ?                                          Yes                          Yes                                 Diuretic                                
  Bepridil                        0.6            Yes                       C                                                     Not evaluated                              Yes                          Yes                                 Ca channel blocker                      
  Furazolidone                    0.6            None observed             B                                                     Contraindicated in infants \< one month    Yes                          Yes                                 Anti-protozoal                          
  Nefazodone hydrochloride        0.6            Yes                       C                                                     Not evaluated                              Yes                          yes                                 Anti-depressant                         
  Curcumin                        0.5            None observed             ?                                                     Yes?                                       Yes                          Yes                                 Hepatoprotective agent                  Experimental drug
  Diacerein                       0.5            Not evaluated             ?                                                     Not evaluated                              Yes                          Yes                                 Osteoarthritis drug                     
  Isoniazid                       0.5            Yes                       C                                                     Yes                                        Yes                          Yes                                 Anti-TB                                 
                                                                                                                                                                                                                                                                                     
  *2nd Priority hits*                                                                                                                                                                                                                                                                
  Ethosuximide                    2              Yes                       C                                                     Not evaluated in children under 3 years    Yes                          Anti-epileptic                                                              
  Piracetam                       1.6            Not evaluated             ?                                                     Not evaluated                              Yes                          Nootropic                                                                   
  Sulfamethizole                  1.6            Yes                       Not safe                                              Not evaluated                              Yes                          Anti-biotic                                                                 
  Nevirapine                      1.5            None observed             B                                                     Approved                                   Yes                          Anti-viral                                                                  
  Oxycodone hydrochloride         1.4            None observed             B                                                     Not evaluated                              Yes                          Opioid agonist                                                              
  Sulfaguanidine                  1.4            Yes                       ?                                                     Not evaluated                              Yes                          Sulfa drug                                                                  
  Valacyclovir hydrochloride      1.3            None observed             B                                                     Not evaluated in children under 2 years    Yes                          Anti-viral                                                                  
  Ibuprofen                       1.2            Yes?                      C                                                     Not evaluated                              Yes                          Non-steroidal anti-inflammatory                                             
  Phenytoin                       1              Yes                       D                                                     Yes                                        Yes                          Anti-eplieptic                                                              
  Mefexamide hydrochloride        0.9            Not evaluated             ?                                                     Not evaluated                              Yes                          Anti-depressant                                                             
  Nitrazepam                      0.9            Yes                       D                                                     Yes                                        Yes                          Hypnotic                                                                    
  Benznidazole                    0.8            Not evaluated             ?                                                     Not evaluated                              Yes                          Anti-parasitic                                                              
  Sorbic acid                     0.8            None observed             B                                                     ?                                          Yes                          Anti-infective, food preservative                                           
  Acyclovir                       0.7            None observed             B                                                     Not evaluated in children under 2 years    Yes                          Anti-viral                                                                  
  Tolterodine tartrate            0.7            Yes                       C                                                     not evaluated                              Yes                          Muscle relaxant                                                             
  Trifluperidol                   0.7            Not evaluated             ?                                                     Not evaluated in children under 6 years    Yes                          Anti-psychotic                                                              
  Benzydamine hydrochloride       0.6            No contraindications      ?                                                     ?                                          Yes                          Non-steroidal anti-inflammatory                                             
  Bumetanide                      0.6            Yes                       C                                                     Not evaluated in children under 18 years   Yes                          Anti-hypertensive                                                           
  Riboflavin                      0.6            None observed             ?                                                     ?                                          Yes                          Micronutrient                       Micronutrient                           
  Phytonadione                    0.5            None observed             C                                                     Not evaluated in pediatric populations     Yes                          Micronutrient                                                               
  Pyrimethamine                   0.5            Yes                       C                                                     Yes                                        Yes                          Anti-parasitic                                                              
                                                                                                                                                                                                                                                                                     
  *Deprioritised*                                                                                                                                                                                                                                                                    
  Kitasamycin                     2.1            ?                         ?                                                     ?                                          Yes                          Anti-biotic, macrolide              Safe for lifestock                      
  Ciprofloxacin hydrochloride     2              None observed             C                                                     Approved                                   Yes                          Yes                                 Anti-biotic                             Tested previously ([@b0080])
  Oxfendazole                     1.2            Not evaluated             ?                                                     Not evaluated                              Yes                          Anti-helmintic                      Safe for lifestock                      
  Sodium Caseinate                1.2            None observed             A                                                     Approved                                   Nd                           Nutrient                                                                    
  Morantel Tartrate               1.1            Not evaluated             ?                                                     Not evaluated                              Yes                          Anti-helminthic                     Safe for lifestock                      
  Benactyzine (Hydrochloride)     1              Not evaluated             ?                                                     Not evaluated                              Yes                          Yes                                 Anti-cholinergic                        No longer widely used in medicine due to side effects
  Neratinib                       1              Not evaluated             ?                                                     Not evaluated                              Nd                           Inhibitor of ErbB1 and ErbB2        Phase I compound                        
  Eliprodil                       0.9            Not evaluated             ?                                                     Not evaluated                              No                           NMDA receptor antagonist            Other NMDA antagonists are category B   
  Geftinib                        0.9            Yes                       D                                                     Not evaluated                              Yes                          Yes                                 Anti-neoplastic                         In clinical trials
  Narasin                         0.9            Not evaluated             ?                                                     Not evaluated                              Yes                          Yes                                 Anti-biotic                             Safe for lifestock
  Dichlorophen                    0.7            Not evaluated             ?                                                     Not evaluated                              Yes                          Yes                                 Anti-parasitic                          Safe for lifestock
  L-Dopa                          0.8            Yes                       C                                                     Not evaluated                              No                           Yes                                 Dopamine enhancer                       
  Selenium Powder                 0.8            Safe                      Safe                                                  Not evaluated                              No                           Yes                                 Nutrient supplement                     
  Nitrofurantoin                  0.7            None observed             B                                                     Contraindicated in infants \< one month    Nd                           Anti-biotic                                                                 
  Quinidine                       0.7            Yes                       C                                                     Yes                                        No                           Na-antagonist                                                               
  Ubenimex                        0.7            Not evaluated             ?                                                     Not evaluated                              No                           Aminopeptidase inhibitor            In clinical trials                      
  Baclofen                        0.6            Yes                       C                                                     Not evaluated in children under 12 years   No                           Yes                                 Muscle relaxant                         
  Chlorphenesin Carbamate         0.6            None observed             ?                                                     Not evaluated                              No                           Muscle relaxant                                                             
  Dasatinib                       0.6            Yes                       D                                                     Not evaluated in children under 18 years   No                           Anti-neoplastic                                                             
  Nicarbazin                      0.6            Not evaluated             ?                                                     Not evaluated                              Yes                          Yes                                 Anti-biotic                             Safe for lifestock
  Sulfanitran                     0.6            Not evaluated             ?                                                     Not evaluated                              Yes                          Anti-protozoal                      Safe for lifestock                      
  Trifluoperazine hydrochloride   0.6            Yes                       C                                                     Not evaluated in children under 6 years    No                           Yes                                 Anti-psychotic                          Long-term medication
  Betazole hydrochloride          0.5            Not evaluated             ?                                                     Not evaluated                              No                           Histamine analogue                  Diagnostic agent                        
  Carbinoxamine maleate           0.5            Not evaluated             C                                                     Yes                                        No                           Anti-histamine                                                              
  Diflunisal                      0.5            Yes                       C                                                     Not evaluated in children under 12 years   No                           Yes                                 Non-steroidal anti-inflammatory         
  Fluoxetine hydrochloride        0.5            Yes                       C                                                     Not evaluated in children under 7 years    No                           Yes                                 Anti-depressant                         
  Hydrochlorothiazide             0.5            None observed             C                                                     Not evaluated in pediatric populations     No                           Anti-hypertensive                                                           
  Isoxsuprine hydrochloride       0.5            Not evaluated             ?                                                     Not evaluated                              Yes                          Vasodilator                         Safe for lifestock                      
  Nilutamide                      0.5            Yes                       C                                                     Not evaluated                              No                           Yes                                 Androgen receptor blocker               
  Scopolamine methylnitrate       0.5            Yes                       C                                                     Not evaluated in pediatric populations     No                           Anti-cholinergic                                                            
  Troleandomycin                  0.5            Yes?                      C                                                     Not evaluated in pediatric populations     Nd                           Anti-biotic                                                                 

Pregnancy categories (US--FDA): A = Adequate and well-controlled studies have failed to demonstrate a risk to the foetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters); B = Animal reproduction studies have failed to demonstrate a risk to the foetus and there are no adequate and well-controlled studies in pregnant women; C = Animal reproduction studies have shown an adverse effect on the foetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks; D = There is positive evidence of human foetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

###### 

Comparison of different classes of antibiotic on O *gutturosa Wolbachia* loads.

  Compound        Class             Concentration (μM)   Reduction in *Wolbachia* (*wsp*:*gst* log drop from vehicle controls)
  --------------- ----------------- -------------------- -----------------------------------------------------------------------
  Doxycycline     Tetracycline      12.5                 0.80
  3.125           0.21                                   
  0.781           0.14                                   
  0.195           0.77                                   
  Ciprofloxacin   Fluoroquinolone   12.5                 0.67
  3.125           0.79                                   
  0.781           0.80                                   
  0.195           0.39                                   
  Moxifloxacin    Fluoroquinolone   12.5                 0.97
  3.125           0.83                                   
  0.781           1.00                                   
  0.195           1.03                                   
  Rifapentine     Rifamycin         12.5                 1.04
  3.125           0.77                                   
  0.781           0.78                                   
  0.195           0.99                                   

###### 

Testing of several prioritised hits in the *L. sigmodontis in vivo* model. The *in vitro* cell based *Wolbachia* reductions and cytotoxicity values are shown for comparison.

  Compound                     Characteristics                   *16S* log drop *in vitro*   Cytotoxicity (%)   *in vivo* dose(s) (MKD[a](#tblfn2){ref-type="table-fn"})   Ls length reduction *in vivo* (%)   *wLs ftsz* log drop *in vivo*
  ---------------------------- --------------------------------- --------------------------- ------------------ ---------------------------------------------------------- ----------------------------------- -------------------------------
  Doxycycline                  Anti-biotic                       1.6                         0                  25,[b](#tblfn3){ref-type="table-fn"} 50                    78.3, 79.4                          2.2, 4.7
  Methacycline hydrochloride   Anti-biotic                       1.8                         0                  10, 50                                                     73.4, 80.5                          3.0, 5.7
  Minocycline                  Anti-biotic                       1.6                         0                  25[b](#tblfn3){ref-type="table-fn"}                        81.7                                3.78
  Paromomycin sulfate          Anti-biotic                       1.7                         0                  25                                                         0                                   1.5
  Rifapentine                  Anti-TB                           1.7                         20                 50                                                         68.3                                3.0
  Indomethacin                 Non-steroidal anti-inflammatory   1.7                         0                  15                                                         0                                   1.0
  Abacavir sulfate             Anti-viral                        1                           0                  200                                                        0                                   N.D.
  Sparfloxacin                 Anti-biotic                       1                           0                  25,[b](#tblfn3){ref-type="table-fn"} 130                   28.6, 77.4                          0.6, 5.7
  Ciprofloxacin                Anti-biotic                       2                           0                  100                                                        17.56                               0.46
  Docusate calcium             Laxative                          0.8                         0                  200                                                        20.0                                1.0
  Loratadine                   Allergy medication                0.8                         20.7               0.3, 1, 3                                                  0, 0, 0                             0.2, 0, 0.35
  Ethoxzolamide                Diuretic                          0.7                         19                 200                                                        0                                   0
  Isoniazid                    Anti-TB                           0.5                         0.3                25                                                         0                                   1.0
  Curcumin                     Hepatoprotective agent            0.5                         0                  100                                                        0                                   N.D.
  Nilutamide                   Androgen receptor blocker         0.5                         0.01               5                                                          12.6                                2.3
  Diacerein                    Osteoarthritis drug               0.5                         0                  100                                                        0                                   1.3

MKD = mg/kg/day.

25 MKD given for 10 days.

[^1]: These authors contributed equally to this work.
